PROVENGE is the only FDA-approved immunotherapy made from a patient’s own immune cells for the treatment of prostate cancer. More than 30,000 men have been prescribed PROVENGE, and it has been ...
Add Yahoo as a preferred source to see more of our stories on Google. Sep. 23—MORGANTOWN — Mon Health System has begun offering a specialized prostate cancer immunotherapy treatment not available ...
The Phase 3 IMPACT trial included a crossover design that allowed patients who were randomized to the control arm and experienced disease progression the opportunity to participate in an open label ...
Sipuleucel-T prolonged PSA doubling time in patients with androgen-dependent prostate cancer. CHICAGO—Sipuleucel-T (Provenge), an experimental immunotherapy, is safe and potentially beneficial in men ...
DURHAM, N.C. – Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses. That ...
The John Theurer Cancer Center at Hackensack University Medical is the only cancer center in New Jersey where advanced prostate cancer patients can receive a cell collection process and infusion of ...
BioVest’s immunotherapy BiovaxID®, if approved for follicular lymphoma, will likely gain acceptance on the market more quickly than the Dendreon’s prostate cancer vaccine Provenge, which was the first ...
announced today that four abstracts featuring PROVENGE^® (sipuleucel-T) data from ongoing Phase II sequencing studies and the PROCEED registry, and two abstracts highlighting preliminary Phase II data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results